Halozyme to Report First Quarter 2026 Financial and Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
| Halozyme Therapeutics, Inc. (NASDAQ: HALO) | Delayed: 111.08 +0.66 (0.60%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $110.42 | 52 Week High | $18.39 | |||
| Open | $110.19 | 52 Week Low | $6.96 | |||
| Day High | $112.43 | P/E | N/A | |||
| Day Low | $109.96 | EPS | $-0.58 | |||
| Volume | 1,660,325 | |||||
